# Rosuvastatin to Decrease Residual Immune Activation in HIV Infection

> **NCT01874743** · PHASE2 · UNKNOWN · sponsor: **Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba** · enrollment: 40 (estimated)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Rosuvastatin 20 mg/day

## Key facts

- **NCT ID:** NCT01874743
- **Lead sponsor:** Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01874743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01874743, "Rosuvastatin to Decrease Residual Immune Activation in HIV Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01874743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*